Citations

Clear

6055 citation(s) found for "Vu, Peter".

Outcomes of Relapsed or Refractory Diffuse Large B‐Cell Lymphoma Treated With R‐ GemOx : A Multicenter Cohort Study
Yamshon, Samuel , Koff, Jean L. , Larson, Melissa C. , Kahl, Brad S. , Casulo, Carla , Lossos, Izidore S. , Haddadi, Sara , Stanchina, Michele , Chihara, Dai , Ayers, Amy , Khurana, Arushi , Nowakowski, Grzegorz S. , Reicks, Tanner W., Cohen, Jonathon B. , Martin, Peter , Li, Jia , Shewade, Ashwini, Batlevi, Connie Lee , Lo‐Rossi, Andrea, Fox, David , Masaquel, Anthony, Mun, Yong, Flowers, Christopher R. , Habermann, Thomas , Wang, Yucai , Khurana, Arushi , Nowakowski, Grzegorz S , Farooq, Umar , Link, Brian K , Cohen, Jonathon B , Li, Jia , Shewade, Ashwini , Batlevi, Connie L , Lo-Rossi, Andrea , Fox, David , Masaquel, Anthony , Cerhan, James R , Maurer, Matthew , Kahl, Brad S , Koff, Jean L , Chihara, Dai , Casulo, Carla , Larson, Melissa C , Habermann, Thomas M. , Wang, Yucai , Link, Brian K. , Cerhan, James R. , Maurer, Matthew J. , Nastoupil, Loretta J.

Mayo Clinic

American Journal of Hematology | February 7, 2025 | Volume: 100 | Issue: 4 | Pages: 606-615

10.1002/ajh.27630 | PMID 39918101 Get It

ABSTRACT Rituximab, gemcitabine, and oxaliplatin (R‐GemOx) is a commonly used chemoimmunotherapy regimen for relapsed or refractory (R/R) diffuse large B‐cell lymphoma (DLBCL), but there are limited real‐world data. In a multicenter retrospective study from a cohort of eight US academic centers (LEO CReWE), we evaluated 183 patients with R/R DLBCL and high‐grade B cell lymphoma treated with R‐GemOx, including subgroups treated without intent for consolidation with autologous stem cell transplant (ASCT) or chimeric antigen receptor (CAR) T cell therapy ( n = 100), those utilizing R‐GemOx as a bridge to ASCT or CAR T ( n = 83), and those aged 70 and older ( n = 71). Overall response rates (ORRs) for all patients treated with R‐GemOx were 45% with a complete response (CR) rate of 29%. The median event‐free survival (EFS) was 2.3 months, and the median overall survival (OS) was 13.5 months. Patients receiving R‐GemOx without intent for ASCT or CAR T had ORR and CR rates of 33% and 18%, respectively, with median EFS and OS of 2.0 and 9.5 months, respectively. Patients receiving R‐GemOx as a bridge to ASCT or CAR T had ORR and CR rates of 57% and 36%, respectively, with median EFS and OS of 3.5 and 17.4 months, respectively. Patients receiving R‐GemOx aged 70 and older had ORR and CR rates of 53% and 33%, respectively, with median EFS and OS of 2.2 and 13.9 months, respectively. These data provide a benchmark for R‐GemOx in the rapidly evolving landscape of R/R DLBCL therapies.
Advanced External Beam Stereotactic Radiotherapy for Skull Base Reirradiation
Wang, He , Alsanea, Fahed , Zhang, X , Liu, Wei , Yang, Jinzhong , Williamson, Tyler D. , Hunter, Rachel , Balter, Peter , Briere, Tina M. , Zhu, Ronald X., Moreno, Amy C. , Reddy, Jay P. , Rosenthal, D.I., Gunn, Gary B., Phan, Jack , Liu, Wei , Yang, Jinzhong , Williamson, Tyler D , Hunter, Rachel A , Briere, Tina M , Moreno, Amy C , Reddy, Jay P , Phan, Jack , Rhee, Dong Joo , Wen, Zhifei , Zhao, Yao Jiang , Lee, Anna , Garden, Adam S. , Gunn, Gary B.

Mayo Clinic

Cancers | February 6, 2025 | Volume: 17 | Issue: 3 | Pages: 540

10.3390/cancers17030540 | PMID 39941906 Get It

Background/Objectives: Stereotactic body radiation therapy (SBRT) for skull base reirradiation is particularly challenging, as patients have already received substantial radiation doses to the region, and nearby normal organs may have approached their tolerance limit from prior treatments. In this study, we reviewed the characteristics and capabilities of four advanced external beam radiation delivery systems and four modern treatment planning systems and evaluated the treatment plan quality of each technique using skull base reirradiation patient cases. Methods: SBRT plans were generated for sixteen skull base reirradiation patients using four modalities: the GK plan for the Elekta Leksell Gamma Knife Perfexion/ICON, the CyberKnife (CK) plan for the Accuray CyberKnife, the intensity-modulated proton therapy (IMPT) plan for the Hitachi ProBeat-FR proton therapy machine, and the volumetric-modulated arc therapy (VMAT) plan for the Varian TrueBeam STx. These plans were evaluated and compared using two novel gradient indices in addition to traditional dosimetry metrics for targets and organs at risk (OARs). The steepest border gradient quantified the percent prescription dose fall-off per millimeter at the boundary between the target and adjacent critical structures. This gradient index highlighted the system’s ability to spare nearby critical OARs. The volume gradient assessed the extent of dose spread outside the target toward the patient’s body. Results: All plans achieved comparable target coverage and conformity, while IMPT and VMAT demonstrated significantly better uniformity. The GK plans exhibited the highest border gradient, up to 20.9%/mm, followed by small-spot-size IMPT plans and CK plans. Additionally, IMPT plans showed the benefit of reduced dose spread in low-dose regions and the lowest maximum and mean doses to the brainstem and carotid artery. Conclusions: The advanced external beam radiotherapy modalities evaluated in this study are well-suited for SBRT in skull base reirradiation, which demands precise targeting of tumors with highly conformal doses and steep dose gradients to protect nearby normal structures.
Endovascular Treatment of Stroke Due to Medium-Vessel Occlusion
Goyal, Mayank , Möhlenbruch, Markus , Nimjee, Shahid M. , Buck, Brian , Kennedy, James , Zhang, Liqun , Hametner, Christian , Nardai, Sándor , Zafar, Atif , Diprose, William K. , Vatanpour, Shabnam , Stebner, Alexander, Bosshart, Salome , Uchida, Kazutaka , Ryckborst, Karla J., Fahed, Robert, Hu, Sherry , Zaidi, Syed , Lee, Vivien , Teal, Rachel, Trivedi, Anurag , Ogungbemi, Ayokunle, Orosz, Péter , Abdalkader, Mohamad , Taschner, Christian , Tarpley, Jason , Poli, Sven , Sahlas, Demetrios J. , Burns, Paul , Marigold, Richard , Amole, Adewumi, Field, Thalia S. , Settecase, Fabio , Lenzsér, Gábor, Asdaghi, Negar , Lobotesis, Kyriakos , Siddiqui, Adnan H. , Berrouschot, J., Ebersole, Koji , Schneider, Hauke , Mandzia, Jennifer, Klostranec, Jesse , Jadun, Changez, Patankar, Tufail , Sauvageau, Eric , Lenthall, Robert , Peeling, Lissa, Budzik, Ronald F. , Lee, Seon-Kyu, Perry, Richard , Hlaing, Thant , Singh, Paul, Hill, Michael D. , Vakharia, Kunal , Harston, George , Möhlenbruch, Markus A , Nimjee, Shahid M , Buck, Brian H , Kennedy, James , Zhang, Liqun , Hametner, Christian , Diprose, William , Vatanpour, Shabnam , Stebner, Alexander , Bosshart, Salome , Singh, Nishita , Hu, Sherry X , Vollherbst, Dominik F , Lee, Vivien H , Rempel, Jeremy L , Teal, Rachel , Trivedi, Anurag , Bode, Felix J , Abdalkader, Mohamad , Poli, Sven , Singh, Ravinder-Jeet , Lopez, George , Schaafsma, Joanna D , Marigold, Richard , Field, Thalia S , Settecase, Fabio , Ortega-Gutierrez, Santiago , Mokin, Maxim , Ebersole, Koji , Schneider, Hauke , Yoo, Albert J , Klostranec, Jesse , Lenthall, Robert , Huynh, Thien , Budzik, Ronald , Levitt, Michael R , Jahromi, Babak S , Hill, Michael D , Siddiqui, Adnan H , Ospel, Johanna M. , Ganesh, Aravind , Dowlatshahi, Dar , Volders, David , Jumaa, Mouhammad , Booth, Thomas Calvert , Shankar, Jai , Dorn, Franziska , Sebastian, Ivy Anne , Fahed, Robert , Lynch, Jeremy , Bode, Felix J. , Pham, Mirko , Leacy, Reade De , Chen, Michael , Reich, Arno , Swartz, Richard H. , Yoo, Albert J. , Huynh, Thien , Makalanda, Levansri , Levitt, Michael R. , Jahromi, Babak S. , Demchuk, Andrew M.

Mayo Clinic

New England Journal of Medicine | February 5, 2025 | Volume: 392 | Issue: 14 | Pages: 1385-1395

10.1056/nejmoa2411668 | PMID 39908448 Get It

Positive pressure ventilation improves oxygen saturation at altitude during recreational aviation: A pilot study
Taylor, Jenna L. , Downs, Aidan K., Danner, Crystal L., Downs, John B. , Donkor, Joshua, Johnston, Jessica I., Rozendaal, Douglas, Johnson, Bruce D. , Summerfield, Douglas T. , Downs, J Hunter, Donkor, Josh, Taylor, Jenna L , Downs, J. Hunter, Larsen, Peter

Mayo Clinic

Physiological Reports | February 5, 2025 | Volume: 13 | Issue: 3 | Pages: No page available

10.14814/phy2.70210 | PMID 39905686 Get It

AbstractAimWe investigated whether a commercial bi‐level positive airway pressure (BPAP) device, would improve peripheral oxygen saturation (SpO2) during recreational aviation up to 12,500 feet without supplemental oxygen. Ten adults with recreational flight experience (age:47 ± 14; female = 5) completed a standardized flight profile in an unpressurised aircraft, involving randomized crossover design at 8,000 feet and 12,500 feet with BPAP or control. SpO2, middle cerebral artery velocity (MCAv), heart rate (HR), respiratory rate (RR), and relative tidal volume (TV) index were measured continuously. Psychomotor vigilance test (3‐min) assessed reaction time halfway through taxi and altitude stages. Altitude significantly (p < 0.05) decreased mean SpO2, MCAv, and RR, and increased TV index and HR. There was no effect of altitude (p > 0.05) on reaction time. BPAP increased mean SpO2 at 8,000 feet [Control: 92 ± 1%; BPAP: 94 ± 2%; mean difference (MD) = 2 ± 2%; p = 0.002] and 12,500 feet [Control: 86 ± 4%; BPAP: 89 ± 4%; MD = 2 ± 3%; p = 0.013]. BPAP lowered MCAv at 8,000 feet [Control: 53 ± 10 cm/s; BPAP: 50 ± 9 cm/s; MD = ‐3 ± 2 cm/s; p = 0.001] and 12,500 feet [Control: 52 ± 10 cm/s; BPAP: 50 ± 8 cm/s; MD = ‐2 ± 3 cm/s; p = 0.041]. BPAP increased TV index at 8,000 feet (Control: 6.6 ± 1.3; BPAP:8.1 ± 1.8; MD = 1.9 ± 0.8; p < 0.001) but not 12,500 feet, without effect on RR or reaction time. This study provides preliminary results that BPAP may improve mean SpO2 for recreational aviators up to 12,500 feet without supplemental oxygen.
The landscape of autosomal-dominant Alzheimer’s disease: global distribution and age of onset
Liu, Haiyan , Marsh, Thomas W. , Shi, Xinyu , Bowling, Kevin M. , Ziegemeier, Ellen , Wang, Guoqiao , Cao, Yuchen , Aristel, Alisha, Li, Jessie, Dickson, Alexa , Perrin, Richard J. , Goate, Alison , Fernández, María Victoria , Day, Gregory S. , Doering, Michelle , Daniels, Alisha , Hassenstab, Jason , Supnet, Charlene , Xiong, Chengjie , Berman, Sarah , Ryan, Natalie S. , Huey, Edward D. , Noble, James M. , Roh, Jee Hoon , Laske, Christoph , Sánchez‐Valle, Raquel , Méndez, Patricio Chrem, Chhatwal, Jasmeer P. , Farlow, Martin R. , Xiong, Chengjie , Gordon, Brian A , Ibanez, Laura , Vöglein, Jonathan , Roh, Jee Hoon , Ikeuchi, T , Sánchez-Valle, Raquel , Chhatwal, Jasmeer , Xiong, Chengjie , Rosa-Neto, Pedro , Schofield, Peter R , Bateman, Randall J , Cruchaga, Carlos , Day, Gregory S , Hassenstab, Jason , Fernandez, Maria , Goate, Alison M , Supnet-Bell, Charlene , Berman, Sarah , Noble, James M , Renton, Alan , Gordon, Brian A. , Benzinger, Tammie L.S. , Allegri, Ricardo , Fox, Nick C. , Vöglein, Jonathan , Jucker, Mathias , Ikeuchi, Takeshi , Schofield, Peter R. , Lee, Jae‐Hong , Levey, Allan I. , Lopera, Francisco Javier , Martins, Ralph N. , Niimi, Yoshiki , Bateman, Randall J. , Karch, Celeste M. , McDade, Eric , Llibre‐Guerra, Jorge J.

Mayo Clinic

Brain | February 4, 2025 | Volume: 148 | Issue: 7 | Pages: 2429-2440

10.1093/brain/awaf038 | PMID 39903689 Get It

Abstract We present a comprehensive global analysis of genetic variants associated with autosomal-dominant Alzheimer’s disease (ADAD). A total of 550 variants in the APP, PSEN1 and PSEN2 genes were identified, of which 279 were classified as pathogenic or likely pathogenic based on American College of Medical Genetics and Genomics and the Association for Molecular Pathology criteria, utilizing data from the Dominantly Inherited Alzheimer Network (DIAN), literature and public databases. Symptomatic age at onset (AAO) data were estimated for 227 of these variants, allowing detailed characterization of their frequency, pathogenicity and AAO. Importantly, 226 variants met eligibility criteria for inclusion in disease-modifying clinical trials. Furthermore, we demonstrated the predictive value of mean variant AAO and parental AAO in predicting symptomatic AAO, validated against converters who became symptomatic during follow-up in the DIAN Observational Study. This dataset provides critical insights into the global landscape of ADAD and reveals the genetic and AAO heterogeneity of ADAD variants while refining variant trial eligibility criteria.
Here's to a Future Beyond Reconstructive Surgery for Pelvic Osteomyelitis
Zein, Said El , Melin, Matthew M , Tran, Nho V. , Rose, Peter S. , Berbari, Elie F. , El Zein, Said , Suh, Gina A.

Mayo Clinic

Clinical Infectious Diseases | February 4, 2025 | Volume: 81 | Issue: 2 | Pages: e36-e36

10.1093/cid/ciaf051 | PMID 39903550 Get It

Real‐world clinical experience with serum MOG and AQP4 antibody testing by live versus fixed cell‐based assay
Said, Yana , Filippatou, Angeliki , Tran, Conlan , Rezavi, LuAnn, Guo, Kai , Resto, Yasmin, Chen, John J. , Pittock, Sean J. , Sotirchos, Elias S. , Pittock, S J , Calabresi, Peter A , Sotirchos, Elias S , Chen, John J , Said, Yana , Filippatou, Angeliki G , Smith, Matthew D. , Calabresi, Peter A. , Caturegli, Patrizio , Flanagan, Eoin P.

Mayo Clinic

Annals of Clinical and Translational Neurology | February 4, 2025 | Volume: 12 | Issue: 3 | Pages: 556-564

10.1002/acn3.52310 | PMID 39901660 Get It

Abstract Objective To assess the real‐world performance of a live (LCBA) versus a fixed (FCBA) cell‐based assay for the detection of serum antibodies directed against myelin oligodendrocyte glycoprotein (MOG‐IgG) and aquaporin‐4 (AQP4‐IgG). Methods This was a retrospective study of patients evaluated at a single tertiary academic referral center, with serum testing performed clinically for AQP4‐IgG and/or MOG‐IgG by FCBA and LCBA on the same day. Additionally, frozen banked sera from the same day for patients tested only by one assay were retrieved and tested by the other assay. FCBA was performed by the Johns Hopkins Immunology Laboratory using Euroimmun kits with detection by indirect immunofluorescence (FCBA‐IF), whereas LCBA was performed by the Mayo Clinic Neuroimmunology Laboratory with detection by flow cytometry (LCBA‐FACS). Results Of 594 specimens with paired MOG‐IgG testing, 500 were negative by both assays, 33 were positive by both assays, 56 were positive exclusively by LCBA‐FACS, and 5 were only positive by FCBA‐IF. Overall, MOG‐IgG LCBA‐FACS exhibited 95.1% sensitivity and 97.7% specificity, whereas MOG‐IgG FCBA‐IF had 45.7% sensitivity and 99.8% specificity. Of 577 specimens with paired AQP4‐IgG testing, 503 were negative by both assays, 51 were positive by both assays, 21 were positive exclusively by LCBA‐FACS, and 2 were only positive by FCBA‐IF. Overall, AQP4‐IgG LCBA‐FACS exhibited 97.3% sensitivity and 100% specificity, whereas AQP4‐IgG FCBA‐IF had 71.6% sensitivity and 100% specificity. Interpretation LCBA‐FACS for both MOG‐IgG and AQP4‐IgG had markedly better sensitivity than FCBA‐IF, with similar specificity. The use of FCBA‐IF may result in underrecognition of both MOG antibody‐associated disease (MOGAD) and AQP4‐IgG seropositive neuromyelitis optica spectrum disorder (NMOSD).
Characterization of the Cystic Phenotype Associated with Monoallelic ALG8 and ALG9 Pathogenic Variants
Jawaid, Tabinda , Elbarougy, Doaa E. , Lavu, Sravanthi , Buia, Guillaume, Senum, Sarah R. , Olinger, Eric , Yang, Hana , Bublitz, Joshua T., Ma, Jun , Audrézet, Marie‐Pierre , Madsen, Charles D. , Schauer, R., Baker, Tracy A. , Gregory, Adriana , Orr, Sarah , Barroso‐Gil, Miguel , Neatu, Ruxandra , Joli, Giancarlo, Dahl, Neera K. , Kline, Timothy L. , Jouret, François , Steinman, Theodore I., Watnick, Terry , Larson, Nicholas B. , Halbritter, Jan , Harris, Peter C. , Gastel, Maatje D.A. van , Jawaid, Tabinda , Ma, Jun , Audrézet, Marie-Pierre , Madsen, Charles D , Schauer, Rachel S , Baker, Tracy A , Gregory, Adriana V , Orr, Sarah E , Barroso-Gil, Miguel , Neatu, Ruxandra , Dahl, Neera K , Kline, Timothy L , Gillion, Valentine , Jouret, Francois , Torres, Vicente E , Peters, Dorien J M , Gitomer, Berenice Y , Watnick, Terry J , Chebib, Fouad T , Hogan, Marie C , Olson, Janet E , Larson, Nicholas B , Ars, Elisabet , Halbritter, Jan , Demoulin, Nathalie , Torres, Vicente E , Sayer, John A , Cornec-Le Gall, Emilie , Harris, Peter C , Senum, Sarah R , Elbarougy, Doaa E , Buia, Guillaume, McDonnell, Shannon K. , Dahan, Karin , Perrone, Ronald D. , Peters, Dorien J.M. , Coto, Eliécer , Chebib, Fouad T. , Hogan, Marie C. , Olson, Janet E. , Torres, Vicente E. , Gall, Émilie Cornec-Le

Mayo Clinic

Journal of the American Society of Nephrology | February 3, 2025 | Volume: 36 | Issue: 6 | Pages: 1056-1071

10.1681/asn.0000000613 | PMID 39899384 Get It

Key Points Loss-of-function ALG8 and ALG9 variants were enriched in polycystic kidney/liver groups and International Classification of Diseases–coded cystic individuals in population cohorts. The ALG8 and ALG9 kidney phenotypes were usually mild to moderate, and lower eGFR or kidney failure was rare. ALG8 pathogenic variants sometimes resulted in severe polycystic liver disease. Background Autosomal dominant polycystic kidney disease (ADPKD) is a common, inherited nephropathy often resulting in kidney failure. It is genetically heterogeneous; along with the major genes, PKD1 and PKD2 , at least eight others have been suggested. ALG8 pathogenic variants have been associated with autosomal dominant polycystic liver disease and implicated in ADPKD, while ALG9 has been suggested as an ADPKD gene, but details of the phenotypes and penetrance are unclear. Methods We screened >3900 families with cystic kidneys and/or livers using global approaches to detect ALG8 or ALG9 pathogenic variants. In addition, population cohorts with sequence data (Genomics England 100K Genomics Project, UK Biobank, and Mayo Clinic Biobank [MCBB]) were screened for ALG8 / ALG9 pathogenic variants. Results Multicenter screening of individuals with polycystic kidney and/or liver disease identified 51 (1.3%) ALG8 (7 multiplex) and 23 (0.6%) ALG9 (5 multiplex) families—frequencies that were approximately 10× and approximately 24× greater than nonpolycystic kidney disease controls. Analysis of individuals with polycystic kidney disease phenotypes in 100K Genomics Project, UK Biobank, and MCBB identified nine ALG8 (0.39%) and nine ALG9 (0.39%) families, an enriched frequency over controls. Two individuals had PKD1 and ALG8 pathogenic changes. Eighty-nine percent of individuals with ALG8 mutations with imaging in the entire MCBB had kidney cysts (50%, >10 cysts), with greater median kidney and liver cyst numbers than controls. For ALG9, 78% had kidney cysts (27%, >10 cysts). Individuals with ALG8 mutations typically had mild cystic kidneys with limited enlargement. Liver cysts were common (71%), with enlarged livers (>2L) found in 11 of 62 patients, although surgical intervention was rare. The ALG9 kidney phenotype was also of mild cystic kidneys, but enlarged livers were rare; for both genes, CKD or kidney failure were rare. Conclusions ALG8 and ALG9 are defined as cystic kidney/liver genes but with limited penetrance for lower eGFR.
Waist Circumference, a Body Shape Index, and Molecular Subtypes of Colorectal Cancer: A Pooled Analysis of Four Cohort Studies
Chalitsios, Christos V. , Markozannes, Georgios , Papagiannopoulos, Christos , Aglago, Elom K. , Berndt, Sonja I. , Buchanan, Daniel D. , Campbell, Peter T. , Chan, Andrew T. , Dimou, Niki , Drew, David A. , French, Amy J. , Georgeson, Peter , Giannakis, Marios , Gruber, Stephen B. , Harrison, Tabitha A. , Hullar, Meredith A.J. , Huyghe, Jeroen R. , Newton, Christina C. , Obón‐Santacana, Mireia , Schmit, Stephanie L. , Steinfelder, Robert S. , Zaidi, Syed Hassan Ejaz , Peters, Ulrike , Phipps, Amanda I. , Cao, Yin , Chan, Andrew T , Dimou, Niki , Drew, David A , Georgeson, Peter , Giannakis, Marios , Gruber, Stephen B , Gunter, Marc J , Harrison, Tabitha A , Hoffmeister, Michael , Hsu, Li , Huang, Wen-Yi , Hullar, Meredith A , Huyghe, Jeroen R , Lynch, Brigid M , Moreno, Victor , Newton, Christina C , Nowak, Jonathan A , Obón-Santacana, Mireia , Ogino, Shuji , Qu, Conghui , Schmit, Stephanie L , Steinfelder, Robert S , Sun, Wei , Thomas, Claire E , Toland, Amanda Ewart , Trinh, Quang M , Ugai, Tomotaka , Um, Caroline Y , Van Guelpen, Bethany , Zaidi, Syed H , Murphy, Neil , Peters, Ulrike , Phipps, Amanda I , Tsilidis, Konstantinos K , Buchanan, Daniel D , Campbell, Peter T , Aglago, Elom K , Markozannes, Georgios , Cao, Yin , Gunter, Marc J. , Hoffmeister, Michael , Huang, Wen‐Yi , Moreno, Vı́ctor , Nowak, Jonathan A. , Qu, Conghui , Sun, Wei , Thomas, Claire E. , Trinh, Quang M. , Um, Caroline Y. , Guelpen, Bethany Van , Murphy, Neil , Tsilidis, Konstantinos K.

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | February 3, 2025 | Volume: 34 | Issue: 4 | Pages: 568-577

10.1158/1055-9965.epi-24-1534 | PMID 39898780 Get It

Abstract Background: Waist circumference (WC) and its allometric counterpart, “a body shape index” (ABSI), are risk factors for colorectal cancer; however, it is uncertain whether associations with these body measurements are limited to specific molecular subtypes of the disease. Methods: Data from 2,772 colorectal cancer cases and 3,521 controls were pooled from four cohort studies within the Genetics and Epidemiology of Colorectal Cancer Consortium. Four molecular markers (BRAF mutation, KRAS mutation, CpG island methylator phenotype, and microsatellite instability) were analyzed individually and in combination (Jass types). Multivariable logistic and multinomial logistic models were used to assess the associations of WC and ABSI with overall colorectal cancer risk and, in case-only analyses, to evaluate heterogeneity by molecular subtype, respectively. Results: Higher WC (ORper 5 cm = 1.06, 95% confidence interval, 1.04–1.09) and ABSI (ORper 1-SD = 1.07, 95% confidence interval, 1.00–1.14) were associated with elevated colorectal cancer risk. There was no evidence of heterogeneity between the molecular subtypes. No difference was observed regarding the influence of WC and ABSI on the four major molecular markers in proximal colon, distal colon, and rectal cancers, as well as in early- and late-onset colorectal cancers. Associations did not differ in the Jass-type analysis. Conclusions: Higher WC and ABSI were associated with elevated colorectal cancer risk; however, they do not differentially influence all four major molecular mutations involved in colorectal carcinogenesis but underscore the importance of maintaining a healthy body weight in colorectal cancer prevention. Impact: The proposed results have potential utility in colorectal cancer prevention.
Identifying consensus and areas for future research in chondrosarcoma
Kurisunkal, Vineet , Botello, Eduardo , Boyle, Richard A. , Ebeid, Walid , Houdek, Matthew T. , Puri, Ajay , Brennan, Bernadette , Laitinen, Minna , Jutte, Paul C. , Lazarides, Alexander L. , Verspoor, F.G.M. , Visgauss, Julia D. , Jeys, Lee M , Morris, Guy V , Kurisunkal, Vineet , Botello, Eduardo , Ebeid, Walid , Houdek, Matthew T , Puri, Ajay , Ruggieri, Pietro , Brennan, Bernadette , Laitinen, Minna K , Couch, Cory , Rose, Peter, Sullivan, Mikaela, Tibbo, Meagan, Jutte, Paul , Visgauss, Julia D , Jeys, Lee , Ruggieri, Pietro

Mayo Clinic

The Bone & Joint Journal | February 1, 2025 | Volume: 107-B | Issue: 2 | Pages: 246-252

10.1302/0301-620x.107b2.bjj-2024-0643.r1 | PMID 39889743 Get It

AimsThe Birmingham Orthopaedic Oncology Meeting (BOOM), held in January 2024, convened 309 delegates from 53 countries to discuss and refine 21 consensus statements on the optimal management of chondrosarcoma.MethodsWith representation from Europe (43%; n = 133), North America (17%; n = 53), South America (16%; n = 49), Asia (13%; n = 40), Australasia (5%; n = 16), the Middle East (4%; n = 12), and Africa (2%; n = 6), the combined experience of treating bone sarcomas among attendees totalled approximately 30,000 cases annually, equivalent to 66 years of experience in the UK alone. The meeting’s process began with the formation of a local organizing committee, regional leads, and a scientific committee comprising representatives from 150 specialist units across 47 countries. Supported by major orthopaedic oncology organizations, the meeting used a modified Delphi process to develop consensus statements through online questionnaires, thematic groupings, narrative reviews, and anonymous pre-meeting polling.ResultsStrong (> 80%) consensus was achieved on 19 out of 21 statements, reflecting agreement among delegates. Key areas of consensus included the role of radiology in diagnosis and surveillance, the management of locally recurrent disease, and the treatment of dedifferentiated chondrosarcoma. Notably, there was agreement that routine chemotherapy has no role in chondrosarcoma treatment, and radiological surveillance is safe for intraosseous chondrosarcomas. Despite the overall consensus, areas of controversy remain, particularly regarding the treatment of atypical cartilage tumours and surgical margins. These unresolved issues underscore the need for further research and collaboration within the orthopaedic oncology community.ConclusionBOOM represents the largest global consensus meeting in orthopaedic oncology, providing valuable guidance for clinicians managing chondrosarcoma worldwide. The consensus statements offer a reference for clinical practice, highlight key research priorities, and aim to improve patient outcomes on a global scale.Cite this article: Bone Joint J 2025;107-B(2):246–252.